Literature DB >> 12959503

Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria.

S C J Huijbregts1, L M J De Sonneville, F J Van Spronsen, I E Berends, R Licht, P H Verkerk, J A Sergeant.   

Abstract

This study examined motor control in 61 early and continuously treated patients with phenylketonuria (PKU) and 69 control participants, aged 7 to 14 years. The pursuit task demanded concurrent planning and execution of unpredictable movements, whereas the tracking task required a highly automated circular movement that could be planned in advance. PKU patients showed significantly poorer motor control in both tasks compared with control participants. Deficits were particularly observed for younger patients (age < 11 years). Differences between control participants and PKU patients were significantly greater in the pursuit task compared with the tracking task, indicating more serious deficits when a higher level of controlled processing is required. Correlations with historical phenylalanine levels indicated a later maturation of the level of control required by the pursuit task compared with the tracking task.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12959503     DOI: 10.1037/0894-4105.17.3.369

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  14 in total

Review 1.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria.

Authors:  M Hoeksma; M Van Rijn; P H Verkerk; A M Bosch; M F Mulder; J B C de Klerk; T J de Koning; E Rubio-Gozalbo; M de Vries; P J J Sauer; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease.

Authors:  Sanneke Koekkoek; Laura Eggermont; Leo De Sonneville; Thidakat Jupimai; Saijai Wicharuk; Wichitea Apateerapong; Theshinee Chuenyam; Joep Lange; Ferdinand Wit; Chitsanu Pancharoen; Praphan Phanuphak; Jintanat Ananworanich
Journal:  J Neurol       Date:  2006-11-08       Impact factor: 4.849

4.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

Review 5.  Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?

Authors:  F J van Spronsen; Marieke Hoeksma; Dirk-Jan Reijngoud
Journal:  J Inherit Metab Dis       Date:  2009-01-13       Impact factor: 4.982

6.  State regulation and response inhibition in children with ADHD and children with early- and continuously treated phenylketonuria: an event-related potential comparison.

Authors:  J R Wiersema; J J van der Meere; H Roeyers
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.750

7.  High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial.

Authors:  Amber E ten Hoedt; Leo M J de Sonneville; Baudouin Francois; Nienke M ter Horst; Mirian C H Janssen; M Estela Rubio-Gozalbo; Frits A Wijburg; Carla E M Hollak; Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2010-12-10       Impact factor: 4.982

Review 8.  Mild hyperphenylalaninemia: to treat or not to treat.

Authors:  Francjan J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

9.  Response variability in Attention-Deficit/Hyperactivity Disorder: a neuronal and glial energetics hypothesis.

Authors:  Vivienne A Russell; Robert D Oades; Rosemary Tannock; Peter R Killeen; Judith G Auerbach; Espen B Johansen; Terje Sagvolden
Journal:  Behav Brain Funct       Date:  2006-08-23       Impact factor: 3.759

10.  Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls.

Authors:  Willem G van Ginkel; Rianne Jahja; Stephan C J Huijbregts; Anne Daly; Anita MacDonald; Corinne De Laet; David Cassiman; François Eyskens; Irene M L W Körver-Keularts; Philippe J Goyens; Patrick J McKiernan; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2016-06-29       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.